Table 3.
Exacerbation Duration (In days) By Exacerbation Severity (Mild Or Moderate-To-severe), COPD Severity And Treatment Group
| Erdosteine | Placebo | %Change | P-value | |
|---|---|---|---|---|
| Moderate COPD patients (N=254) | ||||
| All exacerbations | 9.1 (7.4) | 12.3 (9.6) | −26.0 (5.6) | 0.022 |
| Mild exacerbations | 7.7 (4.9) | 9.8 (8.0) | −21.4 (5.0) | 0.037 |
| Moderate-to-severe exacerbations | 10.5 (8.5) | 13.7 (10.4) | −23.4 (4.8) | 0.040 |
| Severe COPD patients (N=191) | ||||
| All exacerbations | 10.9 (7.5) | 12.8 (9.9) | −14.8 (4.7) | 0.093 |
| Mild exacerbations | 8.7 (5.8) | 10.4 (7.8) | −16.3 (4.8) | 0.131 |
| Moderate-to-severe exacerbations | 13.9 (9.8) | 15.0 (11.2) | −7.3 (3.4) | 0.241 |
| All RESTORE patients (N=445) | ||||
| All exacerbations | 9.5 (7.2) | 12.6 (9.7) | −24.6 (5.3) | 0.023 |
| Mild exacerbations | 8.4 (5.2) | 10.4 (8.2) | −19.2 (4.9) | 0.039 |
| Moderate-to-severe exacerbations | 11.1 (8.9) | 14.1 (10.8) | −21.3 (5.2) | 0.041 |
Note: Data are presented as mean (standard deviation) in days.